In addition, multiple randomized controlled trials have shown that there is no proven efficacy of adding antiplatelet therapy (aspirin or P2Y12 inhibitors) to standard thromboprophylaxis or anticoagulant therapy in hospitalised patients with COVID-19 [11], although conceptually antiplatelet therapy, such as P2Y12 inhibitors, may still be an interesting therapeutic option in patients with COVID-19 [12]. The gene discussed is P2RY12; the disease is COVID-19.